BackCg Oncology Overview
Cg Oncology Inc.

Cg Oncology Return on Equity

Valuation check: CGON's ROE is -11.7%, below the sector sector average of 11.64%.

Get informed when a big investor buys or sells

+ Follow

ROE

-11.70%

Return on Equity

-11.70%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Cg Oncology (CGON) FAQ

Cg Oncology (CGON) currently reports a ROE of -11.7%. That is below the sector sector average of 11.64%. Use the charts on this page to explore Cg Oncology's ROE history and peer comparisons.

Cg Oncology's ROE of -11.7% is lower than the its sector sector average of 11.64%. That is roughly 200.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cg Oncology's current -11.7% should be judged against industry norms (sector average: 11.64%) and against CGON's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -11.7%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Cg Oncology, and consider following CGON for alerts when major investors trade the stock.